ClinicalTrials.gg
TerminatedNCT04175613Updated Nov 20, 2026Results posted

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Apremilast in Psoriasis, sponsored by Amgen. Terminated at 50 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now TerminatedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
18th of 44
160 · median 103
Started
2019
with 5 others
Phase 3
18 of 44
none open now
Registered
32nd of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 18th largest by enrollment, is one of 6 that started in 2019, is one of 18 in phase 3, and was the 32nd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy.

The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis
  • CC-10004
  • Apremilast
  • Pediatric
  • Age 6 - 17 years
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject must satisfy the following criteria to be enrolled in the study:

  1. Subject is male or female 6 to 17 years of age, inclusive, at the time the document is signed by the legal guardian.
  2. Subject must have a weight of ≥ 20 kg.
  3. Subjects must have an age and sex specific value no lower in range than the 5th percentile on the Centers for Disease Control (CDC) growth chart for children and adolescents.
  4. Subject must have completed Week 52 (Apremilast Extension Phase) of Study CC-10004-PPSO-003.
  5. Subject is able to sign an assent with a legal guardian/s who understand/s and voluntarily sign/s an informed consent prior to any study-related assessments/procedures being conducted.
  6. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  7. All female subjects of (FCBP) must either practice abstinence from heterosexual contact or use one of the approved options as described below while on apremilast and for at least 28 days after administration of the last dose of apremilast. For the purpose of this study, a female subject is considered of childbearing potential if she is ≥ 12 years old or has reached menarche, whichever occurred first.

At the time of study entry, and at any time during the study when a female subject of childbearing potential's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding abstinence or contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.

Females of childbearing potential must have a negative pregnancy test at each visit. All FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

Option 1: Any one of the following effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy;

OR

Option 2: Male or female condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method:

(a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

NOTE: Option 2 may not be acceptable as a contraception option in all countries per local guidelines/regulations.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has a condition, including the presence of laboratory abnormalities, or psychiatric illness, that would place the subject at unacceptable risk if he/she were to participate in the study.
  2. Subject has a condition that confounds the ability to interpret data from the study.
  3. Subject has evidence of skin conditions, other than psoriasis, that would interfere with clinical assessments.
  4. Subject is pregnant or breastfeeding.
  5. Subject has guttate, erythrodermic, or pustular psoriasis.
  6. Subject has active tuberculosis (TB) or a history of incompletely treated TB.
  7. Subject answers "Yes" to any question on the Columbia-Suicide Severity Rating Scale at Visit 16 of study CC-10004-PPSO-003.
  8. Subject plans concurrent use of the following therapies that may have a possible effect on psoriasis.

    1. Conventional systemic therapy for psoriasis (including but not limited to cyclosporine, , methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters)
    2. Biologic therapy:

    i. Etanercept (or biosimilar) treatment ii. Adalimumab (or biosimilar) treatment iii. Other TNF or interleukin (IL)-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) iv. Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) c) Use of any drug other than apremilast

  9. Subject has prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.
  10. Children in Care: a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Patients treated with Apremilast

    Subjects with a weight between 20 kg to \< 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.

    Drug: Apremilast

Interventions

  • Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study

    Also known as: CC-10004, Otezla

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product. Serious TEAEs were those that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability/incapacity, led to a congenital anomaly/birth defect, or were considered other important medical events. Apremilast-related TEAEs were TEAEs assessed by the investigator as related to the study drug. Severe TEAEs are events causing significant discomfort or pain, requiring medical intervention or drug therapy, and interfering with activities of daily living.

    Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)

  2. Number of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.

    Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)

  3. Change From Baseline in Body Weight

    Change from baseline in body weight was reported.

    Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)

  4. Change From Baseline in Height

    Change from baseline in height of the participants was reported.

    Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)

  5. Change From Baseline in Body Mass Index (BMI)

    Change from baseline in BMI was reported.

    Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)

  6. Number of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

    The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

    Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)

  7. Number of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

    The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

    Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)

Secondary outcomes

  1. Percentage of Participants With a Static Physician Global Assessment (sPGA) Response

    The sPGA is the assessment of whole body psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. sPGA response is defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline in core study.

    Time frame: Weeks 0, 52, 104, 156, and 208.

07

Results

Posted Nov 20, 2026

Participant flow

Participants were enrolled into this study at sites in Belgium, Canada, Czech Republic, France, Israel, Italy, Russia, Spain, and the United States. This study was conducted between 20 December 2019 and 12 December 2025.

Participant flow — Overall Study
MilestoneApremilast
Started160
Received at least one dose of apremilast160
Completed22
Not completed138
Withdrew: Non-compliance with study drug1
Withdrew: Study terminated by sponsor27
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by parent/guardian15
Withdrew: Withdrawal by subject8
Withdrew: Lack of efficacy10
Withdrew: Apremilast commercially available in the country for the pediatric patients8
Withdrew: Turned 18 years old54
Withdrew: Adverse event4
Withdrew: Miscellaneous6

Outcome measures

PrimaryNumber of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of the study. A TEAE is any AE that occurred after first dose of the investigational product. Serious TEAEs were those that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability/incapacity, led to a congenital anomaly/birth defect, or were considered other important medical events. Apremilast-related TEAEs were TEAEs assessed by the investigator as related to the study drug. Severe TEAEs are events causing significant discomfort or pain, requiring medical intervention or drug therapy, and interfering with activities of daily living.

Time frame:
Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
ParticipantsApremilast
TEAE86
Serious TEAE5
Apremilast-related TEAE18
Severe TEAE5
Apremialst-related Serious TEAE1
TEAE Leading to Drug Interruption11
TEAE Leading to Drug Withdrawal6
TEAE Leading to Death0
PrimaryNumber of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a questionnaire that is used to assess suicidal ideation and behavior. The C-SSRS questionnaire measures suicidal ideation, intensity of ideation, and suicidal behaviors. Results presented are for the number of participants who recorded suicidal ideation or behavior on the C-SSRS.

Time frame:
Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS)
ParticipantsApremilast
Number of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS)0
PrimaryChange From Baseline in Body Weight

Change from baseline in body weight was reported.

Time frame:
Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Reported as:
Mean · Kilograms (kg)
Change From Baseline in Body Weight
Kilograms (kg)Apremilast
Change From Baseline in Body Weight7.46 ± 7.915
PrimaryChange From Baseline in Height

Change from baseline in height of the participants was reported.

Time frame:
Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Reported as:
Mean · centimeter (cm)
Change From Baseline in Height
centimeter (cm)Apremilast
Change From Baseline in Height7.67 ± 8.277
PrimaryChange From Baseline in Body Mass Index (BMI)

Change from baseline in BMI was reported.

Time frame:
Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Reported as:
Mean · kilograms per meter square
Change From Baseline in Body Mass Index (BMI)
kilograms per meter squareApremilast
Change From Baseline in Body Mass Index (BMI)1.16 ± 2.082
PrimaryNumber of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the breasts and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

Time frame:
Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Reported as:
Count of participants · Participants
Number of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
ParticipantsApremilast
Breast Growth — Stage 118
Breast Growth — Stage 214
Breast Growth — Stage 39
Breast Growth — Stage 418
Breast Growth — Stage 526
Breast Growth — Missing0
Pubic Hair Growth — Stage 119
Pubic Hair Growth — Stage 214
Pubic Hair Growth — Stage 39
Pubic Hair Growth — Stage 417
Pubic Hair Growth — Stage 526
Pubic Hair Growth — Missing0
Other Changes — Stage 119
Other Changes — Stage 214
Other Changes — Stage 311
Other Changes — Stage 415
Other Changes — Stage 526
Other Changes — Missing0
PrimaryNumber of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development

The Tanner Staging of sexual development is a scale of physical development as children transition into adolescence and then adulthood. The scale defines physical measurements of development based on characteristics, such as the size of the genitals, testicular volume, and growth of pubic hair. The scale ranges from stage I (pre-adolescent) to stage V (adult development). The results presented are for the number of participants at stage I-V of development.

Time frame:
Week 0 through end of Long-term Extension Phase (up to 208 weeks)
Reported as:
Count of participants · Participants
Number of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual Development
ParticipantsApremilast
Testes Growth — Stage 120
Testes Growth — Stage 27
Testes Growth — Stage 311
Testes Growth — Stage 414
Testes Growth — Stage 523
Testes Growth — Missing0
Penis Growth — Stage 120
Penis Growth — Stage 27
Penis Growth — Stage 312
Penis Growth — Stage 412
Penis Growth — Stage 524
Penis Growth — Missing0
Pubic Hair Growth — Stage 119
Pubic Hair Growth — Stage 29
Pubic Hair Growth — Stage 310
Pubic Hair Growth — Stage 415
Pubic Hair Growth — Stage 522
Pubic Hair Growth — Missing0
Other Changes — Stage 121
Other Changes — Stage 27
Other Changes — Stage 39
Other Changes — Stage 414
Other Changes — Stage 523
Other Changes — Missing1
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) Response

The sPGA is the assessment of whole body psoriasis at the time of evaluation. The sPGA is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. sPGA response is defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline in core study.

Time frame:
Weeks 0, 52, 104, 156, and 208.
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response
percentage of participantsApremilast
Week 060
Week 5257.8
Week 10465.9
Week 15667.3
Week 20865.2

Adverse events

Collected over Week 0 through end of Long-term Extension Phase (up to 208 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apremilast 20 mg BID0/74 (0%)2/74 (2.7%)27/74 (36.5%)
Apremilast 30 mg BID0/86 (0%)3/86 (3.5%)25/86 (29.1%)
Apremilast BID0/160 (0%)5/160 (3.1%)52/160 (32.5%)
Most frequent serious events
Most frequent serious events
EventApremilast 20 mg BIDApremilast 30 mg BIDApremilast BID
Abdominal painGastrointestinal disorders1/740/861/160
Acute kidney injuryRenal and urinary disorders1/740/861/160
PhimosisCongenital, familial and genetic disorders0/741/861/160
HeadacheNervous system disorders0/741/861/160
Suicidal ideationPsychiatric disorders0/741/861/160
Most frequent other events
Most frequent other events
EventApremilast 20 mg BIDApremilast 30 mg BIDApremilast BID
InfluenzaInfections and infestations6/741/867/160
PsoriasisSkin and subcutaneous tissue disorders4/746/8610/160
Abdominal painGastrointestinal disorders5/741/866/160
VomitingGastrointestinal disorders5/744/869/160
COVID-19Infections and infestations5/744/869/160
HeadacheNervous system disorders5/744/869/160
Respiratory tract infection viralInfections and infestations3/745/868/160
Viral upper respiratory tract infectionInfections and infestations4/744/868/160

Baseline characteristics

Long-term Extension Treatment Population: all participants who received at least one dose of apremilast.

Age, Continuous
Age, Continuous(years)Apremilast
Mean12.9 ± 3.13
Sex: Female, Male
Sex: Female, Male(Participants)Apremilast
Female85
Male75
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Apremilast
Hispanic or Latino19
Not Hispanic or Latino136
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Apremilast
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American3
White149
More than one race0
Unknown or Not Reported4
Body Weight
Body Weight(kilograms (kg))Apremilast
Mean51.70 ± 20.84
Height
Height(centimeters (cm))Apremilast
Mean155 ± 16.56
Body Mass Index
Body Mass Index(kilograms per meter square)Apremilast
Mean20.76 ± 5.04
08

Study locations

50 sites
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Johnson Dermatology Clinic
    Fort Smith, Arkansas 72916, United States
  • First OC Dermatology
    Irvine, California 92697, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • California Dermatology Institute
    Thousand Oaks, California 91320, United States
  • Solutions Through Advanced Research Inc
    Jacksonville, Florida 32256, United States
  • Ciocca Dermatology
    Miami, Florida 33173, United States
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217, United States
  • Dawes Fretzin Dermatology Group Inc
    Indianapolis, Indiana 46256, United States
  • Dermatologists of Central States
    Fairborn, Ohio 45324, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Driscoll Childrens Hospital
    San Antonio, Texas 78218, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53715-1375, United States
  • Centre Hospitalier Universitaire Saint Pierre
    Brussels, 1000, Belgium
  • Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Stollery Childrens Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Winnipeg Clinic Dermatology Research
    Winnipeg, Manitoba R3C 0N2, Canada
  • Karma Clinical Trials
    St. John's, Newfoundland and Labrador A1C 2H5, Canada
  • AvantDerm
    Toronto, Ontario M5A 3R6, Canada
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Synexus Czech sro
    Prague, 120 00, Czechia
  • Cabinet du Docteur Ruer-Mulard Mireille
    Martigues, 13500, France
  • Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
    Toulouse, 31400, France
  • Soroka University Medical Center
    Bear Sheva, 8410101, Israel
  • Azienda Ospedaliero Universitaria Di Cagliari
    Cagliari, 09124, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35020, Italy
  • Altai State Medical University
    Barnaul, 656038, Russia
  • Chelyabinsk Regional Clinical Skin and Venereal Dispensary
    Chelyabinsk, 454048, Russia
  • Republican Clinical Dermatology and Venerology Dispensary
    Kazan', 420012, Russia
  • Clinical Dispensary of Dermatology and Venereology of Krasnodar Territory of the Ministry of Health
    Krasnodar, 350020, Russia
  • State Scientific Center for Dermatovenereology and Cosmetology
    Moscow, 107076, Russia
  • Moscow Scientific Practical Center of Dermatology Venerology and Cosmetology
    Moscow, 119071, Russia
  • National Medical Research Center for Children Health
    Moscow, 119991, Russia
  • LLC Medical Center Zdorovaya Semiya
    Novosibirsk, 630099, Russia
  • Pierre Wolkenshtein Skin Diseases Clinic LLC
    Saint Petersburg, 191123, Russia
  • Saint Petersburg State Pediatric Medical University
    Saint Petersburg, 194100, Russia
  • LLC PiterKlinika
    Saint Petersburg, 196158, Russia
  • Bashkiria State Medical University
    Ufa, 450083, Russia
  • Yarosavl State Medical Academy
    Yaroslavl, 150000, Russia
  • Ural Scientific Research Institute of Dermatovenereology and Immunopathology
    Yekaterinburg, 620076, Russia
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, Catalonia 08950, Spain
  • Hospital La Paz
    Madrid, Madrid 28046, Spain
  • General University Hospital of Alicante
    Alicante, 3010, Spain
  • Hopsital Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, 28009, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Marques de Valdecilla
    Santander, 39008, Spain
09

References and documents

Publications

  • Langley RG, Arkin L, Fiorillo L, Eichenfield LF, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller AS. Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial. J Am Acad Dermatol. 2026 Jun;94(6):1777-1780. doi: 10.1016/j.jaad.2026.01.072. Epub 2026 Feb 3. No abstract available. PubMed 41643746 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Oct 2025, 70 months.

Results were first posted in Nov 2026, 1 year after primary completion. A results delay was requested in Aug 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2019
First posted
Nov 25, 2019
StartActual
Dec 20, 2019
Primary completionActual
Oct 30, 2025
CompletionActual
Dec 12, 2025
Results delay requested
Aug 31, 2023
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated
changed Nov 20, 2026
Results
Results posted
posted Nov 20, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 United States, 1 Spain)
  • Dermatologists of Central States · Fairborn, United States
  • Hospital La Paz · Madrid, Spain
Show 2 removed
  • Wright State Physicians · Fairborn, United States
  • Hospital La Paz · Madrid, Spain
Nov 20, 2026
Primary outcomes
1 edited, 6 added, 5 removed
What changed in the outcomes
  • EditedNumber of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS)Time frame: Collected at each study visit throughout the life of the study - up to 4 years → Week 0 through end of Long-term Extension Phase (up to 208 weeks)
  • AddedNumber of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
  • AddedChange From Baseline in Body WeightTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
  • AddedChange From Baseline in HeightTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
  • AddedChange From Baseline in Body Mass Index (BMI)Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
  • AddedNumber of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual DevelopmentTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
  • AddedNumber of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual DevelopmentTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
  • RemovedAdverse Events (AEs)Time frame: Up to approximately 4 years
  • RemovedWeight of patients treated with ApremilastTime frame: Collected at each study visit throughout the life of the study - up to 4 years
  • RemovedMean body mass index of the patient treated with ApremilastTime frame: Collected at each study visit throughout the life of the study - up to 4 years
  • RemovedHeight patients treated with ApremilastTime frame: Collected at each study visit throughout the life of the study - up to 4 years
  • RemovedAssessment of sexual maturityTime frame: Collected every 52 weeks throughout the life of the study - up to 4 years
Nov 20, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of Participants With a Static Physician Global Assessment (sPGA) ResponseTime frame: Collected at each study visit throughout the life of the study - up to 4 years → Weeks 0, 52, 104, 156, and 208.
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Completed→Terminated
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Spain)
    • Dermatologists of Central States · Fairborn, United States
    • Hospital La Paz · Madrid, Spain
    Show 2 removed
    • Wright State Physicians · Fairborn, United States
    • Hospital La Paz · Madrid, Spain
    Primary outcomes 1 edited, 6 added, 5 removed
    What changed in the outcomes
    • EditedNumber of Participants With Suicidal Ideation or Behavior Per the Columbia - Suicide Severity Rating Scale (C-SSRS)Time frame: Collected at each study visit throughout the life of the study - up to 4 years → Week 0 through end of Long-term Extension Phase (up to 208 weeks)
    • AddedNumber of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
    • AddedChange From Baseline in Body WeightTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
    • AddedChange From Baseline in HeightTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
    • AddedChange From Baseline in Body Mass Index (BMI)Time frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
    • AddedNumber of Female Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual DevelopmentTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
    • AddedNumber of Male Participants at Stage I-V of Sexual Development Per Tanner Staging of Sexual DevelopmentTime frame: Week 0 through end of Long-term Extension Phase (up to 208 weeks)
    • RemovedAdverse Events (AEs)Time frame: Up to approximately 4 years
    • RemovedWeight of patients treated with ApremilastTime frame: Collected at each study visit throughout the life of the study - up to 4 years
    • RemovedMean body mass index of the patient treated with ApremilastTime frame: Collected at each study visit throughout the life of the study - up to 4 years
    • RemovedHeight patients treated with ApremilastTime frame: Collected at each study visit throughout the life of the study - up to 4 years
    • RemovedAssessment of sexual maturityTime frame: Collected every 52 weeks throughout the life of the study - up to 4 years
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of Participants With a Static Physician Global Assessment (sPGA) ResponseTime frame: Collected at each study visit throughout the life of the study - up to 4 years → Weeks 0, 52, 104, 156, and 208.
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04175613
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 25, 2019
Start date
Dec 20, 2019
Primary completion
Oct 30, 2025
Completion
Dec 12, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion